Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
CETP inhibitors
Biotech
NewAmsterdam shares more data on lipid-lowering Amgen castoff
NewAmsterdam Pharma is sharing more phase 2 obicetrapib data, including an analysis of a predictor of residual risk for future cardiovascular events.
Gabrielle Masson
Apr 9, 2024 5:30am
NewAmsterdam's Amgen castoff cuts LDL cholesterol in phase 2
Jan 17, 2023 9:15am
NewAmsterdam bags $196M to resurrect Amgen's discarded CETP drug
Jan 14, 2021 8:35am
Esperion tees up to launch cholesterol-busting meds—affordably
Jan 14, 2020 8:30am
ACC: Merck anacetrapib reveal bodes neutral at best for DalCor
Mar 20, 2019 10:19am
Amgen kills off CETP inhibitor after seeing Merck data
Oct 26, 2017 8:45am
